IMMU:NSD-Immunomedics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.94

Change

0.00 (0.00)%

Market Cap

USD 20.31B

Volume

0.24M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Company Website : http://www.immunomedics.com

Address : 300 The American Road, Morris Plains, NJ, United States, 07950

Employees : 366

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.90

52 Week High : 87.64

Short Ratio : 3.15

52 Week Low : 8.80

Shorted Shares : 23,599,028

200 Day Moving Average : 49.32

Shorted Shares Previous Month : 26,647,552

50 Day Moving Average : 86.42

Shares Held By Insiders : 1.37%

Short Percentage : 8.00%

Shares Held by Institutions : 81.31%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.36 (+2.82%)

 USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

+15.96 (+3.08%)

 USD55.27B 18.98 14.64
MRNA Moderna, Inc

-4.64 (-3.58%)

 USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+2.01 (+1.28%)

 USD34.27B 36.37 33.83
SGEN Seagen Inc

+3.03 (+1.63%)

 USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

-0.10 (-0.19%)

 USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

+11.68 (+3.39%)

 USD31.01B N/A N/A
GMAB Genmab A/S

-0.07 (-0.16%)

 USD28.77B 26.59 3.08
BNTX BioNTech SE

+3.11 (+3.06%)

 USD24.46B -99,999.99 N/A
INCY Incyte Corporation

+3.40 (+3.75%)

 USD19.83B 47.64 35.20

ETFs Containing IMMU

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.52 (+0.93%)

 USD0.03B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.04 %

+6.00 (+4.82%)

 USD0.34B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.15 %

+4.10 (+1.83%)

 USD1.28B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.10 %

+2.24 (+1.32%)

 USD3.94B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

+2.49 (+1.64%)

 USD7.04B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+1.01 (+1.59%)

 USD0.16B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.08 %

+7.89 (+1.85%)

 USD1.28B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.08 %

+4.28 (+1.32%)

 USD3.94B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

+0.01 (+0.08%)

 USD1.87B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -52.42% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.42% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 377.81% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 377.81% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 113.36% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.36% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 132.94% N/A N/A 8% F
Risk Adjusted Return 85.27% N/A N/A 90% A-
Market Capitalization 20.31B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.23 N/A N/A N/A N/A
Price / Cash Flow Ratio -91.30 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -80.14% N/A N/A N/A N/A
Return on Assets -25.16% N/A N/A N/A N/A
Debt to Equity Ratio 96.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.15 N/A N/A N/A N/A
Short Percent 8.66% N/A N/A N/A N/A
Beta 2.90 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.